The work is virtual / remote with review of case files as described above. Each case file review is anticipated to take 10-15 minutes to complete.
Preferred Education:
4 Year Degree
Additional Information:
4 openings available.
Internal Number: 01
Diasome Pharmaceuticals, Inc is establishing an Insulin Adjustment Committee (IAC) to be virtually staffed by Certified Diabetes Care and Education Specialist (CDCES) in a contractor role. The purpose of the IAC is to evaluate whether MDI Intensive Insulin Therapy dose adjustment by investigators in a Diasome-sponsored Phase 2b clinical trial in T1D is consistent with protocol specifications.
The IAC member will review glycemic values and insulin dosing data contained in a case-file for a given visit. An assessment of whether protocol-specified insulin adjustment was performed will be based on pre-specfied criteria.
This CDCES IAC member position will be a contractor (1099) nonemployee position, with a consulting and nondisclosure agreement executed with Diasome. Successful candidates will:
1) Demonstrate direct recent intensive insulin therapy decison-making /recommendations in T1D patients using MDI, open-loop pumps, or AID.
2) Have demonstrated advanced skills by acheiving certification in "Insulin Therapy".
3) Have a consulting / contractor practice with general and professional liability insurance.
4) Demonstrate a commitment to T1D care and advances in therapy.
Diasome Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company on a mission to improve the lives of people living with diabetes through groundbreaking treatments that aim to fundamentally transform disease management by restoring physiology. Diasome’s novel cell targeting platform illuminates fundamental understandings of diabetes, one of the world’s fastest growing diseases.With over 10 classes of drugs and 10 different insulins, anti-diabetic medications make up the largest annual revenue generating drug category in the U.S. More Americans die from diabetes every year than from AIDS and breast cancer combined.Diasome is the only company in diabetes drug development that is targeting the body’s own glucose control center to prevent hypoglycemia and help normalize blood glucose for people with diabetes.HDV is a nanoscale, frisbee-shaped carrier that can be customized to target payloads to the liver, whether injected or taken orally.HDV is designed to be accepted and removed by the liver through normal liver metabolism.HDV can be used as an admix or premixed with any commercially available insulin and therefore is compatible with any delivery method, including insulin pump systems.